NLRP3 and inflammatory bowel disease: For instance, the 3,4-methylenedioxy-β-nitrostyrene (MNS) that has been demonstrated to treat inflammasome activation-induced inflammatory bowel disease (IBD), prevents NLRP3-mediated ASC speck formation and oligomerization and inhibits NLRP3 ATPase activity by binding to NLRP3 LRR and NLRP3 NACTH [324, 325].